Getting to goal in newly diagnosed @entity164 2 XXXX using combination drug "subtraction therapy".

@entity1 @entity164 @entity6 @entity4053
BACKGROUND: The treatment of newly diagnosed @entity164 2 @entity6 is diverse, with no clear consensus regarding the initial drug regimen or dosing to achieve optimal glycemic control. METHODS: We treated 44 consecutive @entity1 with newly diagnosed @entity164 2 @entity6 with maximally tolerated doses of pioglitazone 45mg/day, metformin 1000-2000mg/day, and repaglinide 1-4mg before meals. The doses and drugs were subsequently decreased ("subtraction therapy") to achieve optimal glycemic control and minimize side effects. Three primary outcomes were measured: the short term HbA1c response, the long term HbA1c response, and the incidence of @entity4053 . RESULTS: All 44 @entity1 responded with a rapid, progressive decline in their HbA1c levels from 11.43  2.3% to 6.17  0.72% (101  25.1mmol/mol to 44  7.9mmol/mol) by three months, and remained stable thereafter. An HbA1c  <=7.0% ( <=53mmol/mol) was reached within 1-4months in 42 of 44 @entity1 , and in every @entity1 by 12months. Each @entity1 's lowest HbA1c level, 5.65  0.6% (38  6.6mmol/mol), was reached over 6.3  2.9months. @entity1 with initial HbA1c levels >10% (>86mmol/mol) (n=33) responded similarly as those with HbA1c levels <10% (<86mmol/mol) (n=11). Combination drug therapy maintained HbA1c levels between 5.0 and 7.0% (31 and 53mmol/mol) for up to 14.83years. Only one clinically significant hypoglycemic event occurred during 261.08 @entity1 -years of follow-up. CONCLUSIONS: In our experience, combination drug "subtraction therapy" was safe and effective for treating all newly diagnosed @entity164 2 @entity6 @entity1 .
